Menu
Peptide Database
Results
No peptides found
Featured

Use search to browse all 100+ peptides

LL-37

Cathelicidin, hCAP-18, FALL-39, CAP-18

Quick Stats
Studies 2230
Trials 95
Score 1
2023 pubmed 5 citations

Impaired tolerance to the autoantigen LL-37 in acute coronary syndrome.

Chernomordik. Fernando F; Cercek. Bojan B; Zhou. Jianchang J; Zhao. Xiaoning X; Lio. Nicole Wai Man NWM; Chyu. Kuang-Yuh KY; Shah. Prediman K PK; Dimayuga. Paul C PC

Key Findings

  • LL‑37 acts as an autoantigen that activates CD8+CD69+CD137+ T cells in acute coronary syndrome (ACS) patients.
  • The activation is partly regulated by CTLA‑4, not PD‑1, and can be blocked by antibodies against HLA molecules.
  • Higher platelet counts are linked to lower activation of these T cells, suggesting platelets suppress the response.

Practical Outcomes

  • For biohackers, this research does not provide a direct supplement or protocol to improve health. It mainly highlights that LL‑37 can provoke harmful immune activity in heart disease, so any attempts to boost LL‑37 for antimicrobial benefits should be approached with caution, especially in people with cardiovascular risk.

Summary

The study shows that in people with acute heart attacks, a natural protein called LL‑37 triggers a specific type of immune cell (CD8+ T cells) to stay active and form memory, which may worsen the condition. This response is controlled mainly by the immune checkpoint CTLA‑4 and can be dampened by platelets.

Abstract

LL-37 is the only member of the cathelicidin family of antimicrobial peptides in humans and is an autoantigen in several autoimmune diseases and in acute coronary syndrome (ACS). In this report, we profiled the specific T cell response to the autoimmune self-antigen LL-37 and investigated the factors modulating the response in peripheral blood mononuclear cells (PBMCs) of healthy subjects and ACS patients. The activation induced marker (AIM) assay demonstrated differential T cell profiles characterized by the persistence of CD134 and CD137, markers that impair tolerance and promote immune effector and memory response, in ACS compared to Controls. Specifically, CD8+CD69+CD137+ T cells were significantly increased by LL-37 stimulation in ACS PBMCs. T effector cell response to LL-37 were either HLA dependent or independent as determined by blocking with monoclonal antibody to either Class-I HLA or Class-II HLA. Blocking of immune checkpoints PD-1 and CTLA-4 demonstrated the control of self-reactive T cell response to LL-37 was modulated predominantly by CTLA-4. Platelets from healthy controls down-modulated CD8+CD69+CD137+ T cell response to LL-37 in autologous PBMCs. CD8+CD69+CD137+ T cell AIM profile negatively correlated with platelet count in ACS patients. Our report demonstrates that the immune response to the autoantigen LL-37 in ACS patients is characterized specifically by CD8+CD69+CD137+ T cell AIM profile with persistent T cell activation and the generation of immunologic memory. The results provide potentially novel insight into mechanistic pathways of antigen-specific immune signaling in ACS.

Study Information

Provider

pubmed

Year

2023

Date

2023-03-27T00:00:00.000Z

DOI

10.3389/fimmu.2023.1113904

Citations

5

References

62